REFERENCES
1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with
Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
2. Pan Y, Wang L, Feng Z, et al. Characterisation of SARS-CoV-2 variants
in Beijing during 2022: an epidemiological and phylogenetic analysis.
Lancet. 2023;401(10377):664-672.
3. Lam TT, Jia N, Zhang YW, et al. Identifying SARS-CoV-2-related
coronaviruses in Malayan pangolins. Nature. 2020;583(7815):282-285.
4. Zhang S, Qiao S, Yu J, et al. Bat and pangolin coronavirus spike
glycoprotein structures provide insights into SARS-CoV-2 evolution. Nat
Commun. 2021;12(1):1607.
5. Liu Z, Zhou J, Wang X, et al. A pan-sarbecovirus vaccine based on RBD
of SARS-CoV-2 original strain elicits potent neutralizing antibodies
against XBB in non-human primates. Proc Natl Acad Sci U S A.
2023;120(11):e2221713120.
6. Qi H, Liu B, Wang X, Zhang L. The humoral response and antibodies
against SARS-CoV-2 infection. Nat Immunol. 2022;23(7):1008-1020.
7. Lu S, Luo S, Liu C, et al. Induction of significant neutralizing
antibodies against SARS-CoV-2 by a highly attenuated pangolin
coronavirus variant with a 104nt deletion at the 3’-UTR. Emerg Microbes
Infect. 2023;12(1):2151383.